Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures

Journal of Neurochemistry

Volumn 73, Issue 6, 1999, Pages 2469-2476

  McNaught, Kevin St P ^a   Jenner, Peter ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

1 Methyl 4 phenylpyridinium; 6 Hydroxydopamine; Astrocytes; Dopaminergic neurones; Nitric oxide; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMINOGUANIDINE; BUTHIONINE SULFOXIMINE; DIZOCILPINE; GLUTATHIONE; LIPOPOLYSACCHARIDE; N METHYL DEXTRO ASPARTIC ACID; NEUROTOXIN; OXIDOPAMINE;

ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; GLIA CELL; MESENCEPHALON; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NEWBORN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; ASTROCYTES; BUTHIONINE SULFOXIMINE; CELLS, CULTURED; COCULTURE TECHNIQUES; DIZOCILPINE MALEATE; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; EXCITATORY AMINO ACID ANTAGONISTS; GLUTATHIONE; LIPOPOLYSACCHARIDES; MESENCEPHALON; NADH, NADPH OXIDOREDUCTASES; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0032748383     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0732469.x     Document Type: Article

References (45)

1. Akaike L. T., Yoshida M., Miyamoto Y., Sato K., Kohno M., Sasamoto K., Miyazaki S., Ueda S., and Maeda H. (1993) Antagonistic action of imidazolineoxyl N-oxide against endothelium relaxing factor/NO through a radical reaction. Biochemistry 32, 827-832.
2. Alam Z. I., Jenner A., Daniel S. E., Lees A. J., Cairns N., Marsden C. D., Jenner P., and Halliwell B. (1997a) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1195-1203.
3. Alam Z. I., Daniel S. E., Lees A. J., Marsden C. D., Jenner P., and Halliwell B. (1997b) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
4. Banati R. B., Daniel S. E., and Blunt S. B. (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13, 221-227.
5. Barker R. and Johnson A. (1995) Nigral and striatal neurons, in Neural Cell Culture - A Practical Approach (Cohen J. and Wilkin G. P., eds), pp. 25-39. IRL Press, Oxford.
6. Beal F. (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis, in Beyond the Decade of the Brain, Vol. 3: Neuroprotection in Parkinson's T Disease (Olanow W. C. and Jenner P., eds), pp. 215-222. Wells Medical Ltd., Royal Tunbridge Wells, U.K.
7. Boka C., Anglade P., Wallach D., Javoy-Agid F., and Hirsch E. C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154.
8. Bolaños J. P., Peuchen S., Heales S. J. R., Land J. M., and Clark J. B. (1994) Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J. Neurochem. 63, 910-916.
9. Bolaños J. P., Heales S. J. R., Peuchen S., Barker J. E., Land J. M., and Clark J. B. (1996) Nitric oxide-mediated mitochondrial damage: a potential role for glutathione. Free Radic. Biol. Med. 21, 995-1001.
10. Bronstein D. M., Perez-Otano I., Sun V., Sawin M., Chan J., Wu G.-C., Hudson P. M., Kong L.-Y., Hong J.-S., and McMillan M. K. (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704, 112-116.
11. Castaño A., Herrera A. J., Cano J., and Machado A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70, 1584-1592.
12. Chao C. C., Hu S., and Peterson P. K. (1996a) Glia: the not so innocent bystanders. J. Neurovirol. 2, 234-239.
13. Chao C. C., Hu S., Sheng W. S., Bu D., Bukrinsky M. I., and Peterson P. K. (1996b) Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16, 276-284.
14. Dawson V. L., Brahmbhatt H. P., Mong J. A., and Dawson T. M. (1994) Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33, 1425-1430.
15. Desagher S., Glowinski J., and Premont J. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 16, 2553-2568.
16. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Jenner P., and Marsden C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
17. Dexter D. T., Holley A. E., Flitter W. D., Slater T. F., Wells R. F., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9, 92-97.
18. Dringen R. and Hamprecht B. (1997) Involvement of glutathione peroxidase and catalase in the disposal of exogenous hydrogen peroxide by cultured astroglial cells. Brain Res. 759, 67-75.
19. Drukarch B., Schepens E., Jongenelen C. A. M., Stoof J. C., and Langeveld C. H. (1997) Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency. Brain Res. 770, 123-130.
20. Forno S. (1981) Pathology of Parkinson's disease, in Movement Disorders, Neurology 2 (Marsden C. D. and Fahn S., eds), pp. 21-40. Butterworth Scientific, London.
21. Griffith M. J. D., Messent M., MacAllister R. J., and Evans T. W. (1993) Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J. Pharmacol. 110, 963-968.
22. Halliwell B. (1996) Mechanisms involved in the generation of free radicals. Pathol. Biol. (Paris) 44, 6-13.
23. Hirsch E. C., Hunot S., Damier P., and Faucheux B. (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?, in Beyond the Decade of the Brain, Vol. 3: Neuroprotection in Parkinson's Disease (Olanow W. C. and Jenner P., eds), pp. 227-237. Wells Medical Ltd., Royal Tunbridge Wells, U.K.
24. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., and Hirsch E. C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363.
25. Irwin I. and Langsten J. W. (1993) MPTP and Parkinson's disease, in Natural and Synthetic Neurotoxins (Harver A. L., ed), pp. 225-256. Academic Press, London.
26. Jenner P. and Olanow W. C. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (Suppl. 3), S161-S170.
27. Lotharius J., Dugan L. L., and O'Malley K. L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurones. J. Neurosci. 19, 1284-1293.
28. Marriott D. R., Hirst W. D., and Ljungberg M. C. (1995) Astrocytes, in Neural Cell Culture-A Practical Approach (Cohen J. and Wilkin G. P., eds), pp. 85-962E IRL Press, Oxford.
29. McGeer E. G. and McGeer P. L. (1997) The role of the immune system in neurodegenerative disorders. Mov. Disord. 12, 855-858.
30. McNaught K. St. P. and Brown G. C. (1998) Nitric oxide causes glutamate release from brain synaptosomes. J. Neurochem. 70, 1541-1546.
31. McNaught K. St. P. and Jenner P. (1999) Extracellular accumulation of nitric oxide, hydrogen peroxide and glutamate in astrocytic cultures following glutathione depletion, complex 1 inhibition and/or lipopolysaccharide-induced activation. Biochem. Pharmacol. (in press).
32. McNaught K. St. P., Thull U., Carrupt P.-A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., and Marsden C. D. (1996) Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 5, 265-274.
33. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., and Ikebe S. (1994) An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35, 204-210.
34. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., and Nagatsu T. (1994) Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150.
35. Morris C. M. and Edwardson J. A. (1994) Iron immunohistochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3, 277-282.
36. Sagara J.-I., Miura K., and Bannai S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61, 1672-1676.
37. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P., and Marsden C. D. (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697.
38. Sanchez-Ramos J. R., Overvik E., and Ames B. N. (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum in Parkinson's disease brain. Neurodegeneration 3, 197-204.
39. Savolainen H. (1978) Superoxide dismutase and glutathione peroxidase activities in rat brain. Res. Commun. Chem. Pathol. Pharmacol. 21, 173-176.
40. 1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145.
41. Seaton T. A., Jenner P., and Marsden C. D. (1996) Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rats. J. Neural Transm. 103, 315-329.
42. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C. D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355.
43. Stewart V. C., Land J. M., Clark J. B., and Heales S. J. R. (1998) Comparison of mitochondrial respiratory chain enzyme activities in rodent astrocytes and neurones and a human astrocytoma cell line. Neurosci. Lett. 247, 201-203.
44. + toxicity in nigral dopaminergic neurones. Neuroreport 7, 921-923.
45. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., and Corsini G. U. (1992) MK-801 prevents MPTP-induced parkinsonism in primates. J. Neurochem. 59, 133-139.